EvoGenix raises $9 million in oversubscribed IPO
28 July, 2005 by Ruth BeranAntibody therapeutic developer EvoGenix closed its initial public offer (IPO) today oversubscribed, raising AUD$9 million through the issue of 36 million shares at $0.25.
New Chemeq CEO promises 'fresh eyes'
27 July, 2005 by Ruth BeranDavid Williams, the CEO designate of Perth-based antimicrobial specialist Chemeq (ASX:CMQ), begins his new role on August 1 and is excited about running the company.
Biota files claim of up to $430m against GSK
27 July, 2005 by Ruth BeranMelbourne-based biopharma Biota Holdings (ASX:BTA) today took the next step in its lawsuit against GlaxoSmithKline (GSK), filing particulars of loss and damage with the Victorian Supreme Court estimated to be in the range of AUD$308 million to $430 million.
Amrad lands US asthma patent
26 July, 2005 by Graeme O'NeillThe US Patent Office has granted Melbourne biopharma Amrad (ASX:AML) a patent on therapeutic antibodies that recognise for a sub-unit of the interleukin-13 (IL-13) receptor implicated in asthma.
UQ spin-off secures $3.25m for pain therapy
26 July, 2005 by Ruth BeranSpinifex Pharmaceuticals, a drug development company spun out of the University of Queensland, has received a AUD$3.25 million investment commitment to develop therapeutics for the treatment of neuropathic pain.
Chemeq names new CEO
26 July, 2005 by Ruth BeranAntimicrobial specialist Chemeq (ASX:CMQ) has named David Williams its new CEO and director, commencing August 1. Williams was formerly CEO of Epic Energy, a gas transmission company.
First C3 CellSpray XP patient treated
26 July, 2005 by Ruth BeranThe first patient has been treated with Clinical Cell Culture's (C3, ASX:CCE) CellSpray XP at Dortmund Hospital in Germany.
Avexa starts phase IIb trial of HIV drug
25 July, 2005 by Ruth BeranMelbourne-based biotech Avexa (ASX:AVX) has started the phase IIb trial of AVX754, the HIV compound it in-licensed from UK company Shire Pharmaceuticals in January.
Proteome Systems wins technology innovation award
21 July, 2005 by Graeme O'NeillProteome Systems has won a prestigious 2005 Frost and Sullivan Technology Innovation Award for its ingenious Chemical Inkjet Printer (ChIP).
In brief: Pharmaxis, Cochlear, OBJ, Cryptome Pharmaceuticals
21 July, 2005 by Staff WritersOn the back of yesterday's announcement, Pharmaxis (ASX:PXC) has been granted approval from Health Canada to conduct a clinical trial of Bronchitol in patients with cystic fibrosis.
Continence Control Systems starts first human implant recruitment
21 July, 2005 by Ruth BeranBioTech Capital (ASX:BTC) investee company Continence Control Systems International (CCS) has commenced patient recruitment for its severe urinary incontinence treatment, following completion of pre-clinical studies and human ethics approval for human implants.
Pharmaxis drug earns FDA 'orphan' status for cystic fibrosis
20 July, 2005 by Helen SchullerThe US Food and Drug Administration has expanded an 'orphan drug' designation to Pharmaxis' (ASX:PXS) drug Bronchitol, for the additional indication of facilitating mucus clearance in patients with cystic fibrosis.
Peptech, Domantis in new cancer target development
20 July, 2005 by Graeme O'NeillSydney biotech Peptech (ASX:PTD) has signed up with its 36.1 per cent owned UK partner Domantis to develop a domain antibody (dAb) for the cancer target identified by its Sydney joint venture partner Biosceptre.
Narhex hires Polish groups for drug development
18 July, 2005 by Ruth BeranSydney anti-viral drug developer Narhex Life Sciences (ASX:NLS) has signed separate manufacturing research agreements with two Polish organisations to reduce the cost and complexity of manufacturing its HIV protease inhibitor DG-35.
Cantor: why biomarkers will change medicine
18 July, 2005 by Ruth BeranIn five years time, biomarker analysis will deliver inexpensive, reliable tests for disease prognosis, delegates at a joint BioMelbourne and Australian Genome Research Facility event heard last week.
